XML 53 R42.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2023
Statement [LineItems] |
Disclosure of Operating Segment Information |
Operating segment information June 30, 2023 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 191,721 |  |  |  | — |  |  |  | 191,721 |
Grant income |  |  | 3,314,001 |  |  |  | — |  |  |  | 3,314,001 |
Net gain on fair value movement of warrants |  |  |  |  |  |  | 131,896 |  |  |  | 131,896 |
Net gain on foreign exchange |  |  |  |  |  |  | 623,511 |  |  |  | 623,511 |
Interest income |  |  |  |  |  |  | 938,999 |  |  |  | 938,999 |
Total revenue and other income |  |  | 3,505,722 |  |  |  | 1,694,406 |  |  |  | 5,200,128 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Profit/(loss) before income tax expense |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (39,896,348 | )
Total segment assets |  |  | 147,448,990 |  |  |  | — |  |  |  | 147,448,990 |
Total segment liabilities |  |  | 10,979,601 |  |  |  | — |  |  |  | 10,979,601 |
Operating segment information June 30, 202 2 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | 170,369 |  |  |  | — |  |  |  | 170,369 |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 84,018 |  |  |  | — |  |  |  | 84,018 |
Grant income |  |  | 4,459,974 |  |  |  | — |  |  |  | 4,459,974 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | 591,070 |  |  |  | 591,070 |
Net gain on foreign exchange |  |  | — |  |  |  | 1,228,122 |  |  |  | 1,228,122 |
Interest income |  |  | — |  |  |  | 224,520 |  |  |  | 224,520 |
Total revenue and other income |  |  | 4,714,361 |  |  |  | 2,043,712 |  |  |  | 6,758,073 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (33,929,768 | ) |  |  | 1,718,976 |  |  |  | (32,210,792 | )
Profit/(loss) before income tax expense |  |  | (33,929,768 | ) |  |  | 1,718,976 |  |  |  | (32,210,792 | )
Income tax expense |  |  |  |  |  |  |  |  |  |  | (34 | )
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (32,210,826 | )
Total segment assets |  |  | 102,169,550 |  |  |  | — |  |  |  | 102,169,550 |
Total segment liabilities |  |  | 8,092,184 |  |  |  | — |  |  |  | 8,092,184 |
Operating segment information June 30, 2021 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 312,841 |  |  |  | — |  |  |  | 312,841 |
Grant income |  |  | 3,549,965 |  |  |  | — |  |  |  | 3,549,965 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | — |  |  |  | — |
Net gain on foreign exchange |  |  | — |  |  |  | — |  |  |  | — |
Interest income |  |  | — |  |  |  | 105,327 |  |  |  | 105,327 |
Total revenue and other income |  |  | 3,862,806 |  |  |  | 105,327 |  |  |  | 3,968,133 |
Segment Result |  |  | (19,665,904 | ) |  |  | (10,236,687 | ) |  |  | (29,902,591 | )
Profit/(loss) before income tax expense |  |  | (19,665,904 | ) |  |  | (10,236,687 | ) |  |  | (29,902,591 | )
Income tax expense |  |  |  |  |  |  |  |  |  |  | (33 | )
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (29,902,624 | )
Total segment assets |  |  | 82,030,533 |  |  |  | — |  |  |  | 82,030,533 |
Total segment liabilities |  |  | 8,758,922 |  |  |  | — |  |  |  | 8,758,922 |

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | immp_StatementLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration